Advertisement

ASH Recognizes Leaders for Support of Patient Care and Research


Advertisement
Get Permission

The American Society of Hematology (ASH) will honor U.S. Senators Susan Collins (R-ME), Patty Murray (D-WA), Shelley Moore Capito (R-WV), and Tammy Baldwin (D-WI), as well as the patient groups Sick Cells, The Sickle Cell Disease Association of America (SCDAA), and The Sickle Cell Disease Consortium for their leadership on issues of importance to hematology research and practice at the 67th ASH Annual Meeting and Exposition in Orlando, from December 6–9, 2025.

“It is a great pleasure to recognize the critical contributions that these individuals and groups have made to improve care for individuals living with blood disorders,” said Belinda R. Avalos, MD, ASH president. “Their commitment to advancing research and education continues to make a meaningful difference in the lives of patients worldwide and their families.”

ASH Public Service Award

Sens. Collins, Murray, Capito, and Baldwin are the recipients of the 2025 ASH Public Service Award, which recognizes unparalleled leadership by elected public officials on issues affecting hematology practice. Sens. Collins and Murray serve as chair and ranking member, respectively, of the U.S. Senate Committee on Appropriations, and Sens. Capito and Baldwin serve as chair and ranking member, respectively, of the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies.

ASH Outstanding Service Award

Sick Cells, the SCDAA, and the Sickle Cell Disease Consortium are the recipients of the 2025 ASH Outstanding Service Award, which recognizes individuals or organizations in the public or private sector who have displayed effective behind-the-scenes leadership in areas relevant to the mission of the Society.

These three organizations have supported ASH’s advocacy efforts for individuals living with sickle cell disease, including support for the Sickle Cell Disease Comprehensive Care Act.

Advocacy has been a key component of ASH’s Sickle Cell Disease Initiative since its inception a decade ago; the initiative now falls under the portfolio of the recently established ASH Center for Sickle Cell Disease Initiatives.

To learn more, visit www.hematology.org


Advertisement

Advertisement




Advertisement